NCT03816345 2026-03-18
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
National Cancer Institute (NCI)
Phase 1 Recruiting
Clinical Trials
57 trialsNCT07137598 2026-03-06
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Hoffmann-La Roche
Phase 2 Recruiting
NCT06440629 2026-02-05
RA-DRUM
Diakonhjemmet Hospital
Phase 4 Recruiting
NCT06098755 2026-02-04
The Sequestration of Holistic Stress Management Techniques for Adults
Virtual Tribunal Monastery
Phase NA Withdrawn
NCT01351805 2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA Completed
NCT06831994 2025-06-29
Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity
Universitätsklinikum Hamburg-Eppendorf
Phase NA Recruiting
NCT06656169 2025-05-01
Effect of Subcutaneous Polyvidone Collagen Treatment on Hand Recovery in Adult Rheumatoid Arthritis.
Instituto Mexicano del Seguro Social
Phase 1/2 Completed
NCT03976245 2024-11-29
Advanced Therapeutics in Rheumatoid Arthritis (RA)
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase 4 Recruiting
NCT03016013 2024-09-26
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects with Inadequate Response to MTX Due to Treat Moderate and Severe Rheumatoid Arthritis.
RemeGen Co., Ltd.
Phase 3 Completed
NCT06175338 2024-09-19
Study, Evaluating Pharmacokinetics, Pharmacodynamics, Immunogenicity and Safety Profiles of Rituximab Compared to MabThera® in Patients With Rheumatoid Arthritis
Mabscale, LLC
Phase 1 Active not recruiting
NCT01242488 2024-07-17
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT01793519 2024-02-28
STARA
Georgetown University
Phase 4 Unknown
NCT05215509 2024-02-02
RABEX
Rigshospitalet, Denmark
Phase NA Completed
NCT02760433 2023-09-21
CREDO 3
R-Pharm
Phase 3 Completed
NCT04255134 2023-05-18
BIORA-PAIN
St George's, University of London
Phase 4 Completed
NCT02742597 2023-03-17
PACEinMM-ON
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Completed
NCT03656627 2023-02-15
Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease
Alliance Foundation Trials, LLC.
Phase 1 Terminated
NCT00048321 2022-12-05
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
Ionis Pharmaceuticals, Inc.
Phase 2 Completed
NCT03589833 2022-10-25
YISTAR
Peking Union Medical College Hospital
Phase 4 Completed
NCT03449758 2022-04-28
SariPRO
Sanofi
Phase 4 Completed
NCT00837434 2021-09-22
Anti-TNF Agents for the Treatment of Rheumatoid Arthritis
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 4 Completed
NCT01960855 2021-08-24
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
AbbVie
Phase 2 Completed
NCT02092467 2021-08-17
Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Pfizer
Phase 4 Completed
NCT01548768 2020-11-27
RHYTHM
Columbia University
Phase 4 Completed
NCT03001219 2020-01-29
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
Hoffmann-La Roche
Phase 2 Terminated
NCT02102594 2019-12-03
TAVAB
Charite University, Berlin, Germany
Phase 2 Terminated
NCT01721044 2019-09-18
RA-BEACON
Eli Lilly and Company
Phase 3 Completed
NCT01590966 2019-08-26
SCINTRA
University Hospital, Ghent
Phase 3 Completed
NCT02475486 2019-06-26
ANSRA
Centre Hospitalier Universitaire de Saint Etienne
Phase NA Completed
NCT02882087 2019-04-03
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
RemeGen Co., Ltd.
Phase 2 Terminated
NCT01907230 2019-03-13
Entecavir for Biological Agents Associated HBV Reactivation in Inflammatory Arthritis Patients
Taipei Veterans General Hospital, Taiwan
Phase 4 Unknown
NCT00094562 2019-01-18
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00960440 2018-12-19
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Pfizer
Phase 3 Completed
NCT02046603 2018-12-07
ACT-MOVE
Hoffmann-La Roche
Phase 3 Completed
NCT03736044 2018-11-08
Reconstitution of CD4+CD25highCD127low/-Tcell
University Hospital of Ferrara
Phase NA Completed
NCT02862574 2018-06-27
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Gilead Sciences
Phase 2 Terminated
NCT02440906 2017-10-03
WIN
University of Florida
Phase NA Completed
NCT00503425 2017-08-15
A Study of MabThera (Rituximab) in Participants With Rheumatoid Arthritis Who Have Had an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARD) and/or Anti-Tumor Necrosis Factor (Anti-TNF) Therapy.
Hoffmann-La Roche
Phase 3 Completed
NCT00185848 2017-03-14
Assessing the Suitability of an Imaging Probe for Use in Clinical Cell and Gene Therapy Trials in Cancer and Rheumatoid Arthritis
Stanford University
Phase 1 Completed
NCT00357903 2017-02-09
Open-Label Extension Treatment With Etanercept (TNFR:Fc) for Participating Patients in Etanercept (TNFR:Fc) Clinical Trials
Amgen
Phase 3 Completed
NCT02109289 2017-02-07
Etanercept in Rheumatoid Arthritis and Vascular Inflammation
Innovaderm Research Inc.
Phase 4 Terminated
NCT01295151 2016-11-02
SWITCH
University of Leeds
Phase 4 Completed
NCT01715896 2016-10-31
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
MedImmune LLC
Phase 2 Completed
NCT02519387 2016-07-20
Efficacy and Safety of Buprenorphine Transdermal Patch in Non-cancer Pain of Moderate Intensity
Mundipharma Pharmaceuticals Sdn. Bhd.
Phase 4 Completed
NCT01350804 2016-05-23
NURTURE 1
Novartis
Phase 3 Completed
NCT01390545 2016-04-13
VELVET
Takeda
Phase 2 Terminated
NCT00883753 2014-08-06
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Hoffmann-La Roche
Phase 3 Completed
NCT00361335 2014-07-29
A Study of Safety and Effectiveness of Golimumab in Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
Centocor, Inc.
Phase 3 Completed
NCT01283971 2014-02-10
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor
Hoffmann-La Roche
Phase 4 Terminated
NCT01009879 2013-07-02
Human Tumor Necrosis Factor Alpha (TNFa)-Induced Pre-B Cell Bone Marrow Emigrants
University of Pittsburgh
Phase 4 Withdrawn